S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Investors Face September Deadline in Bloom Energy Securities Lawsuit

Investors who purchased Bloom Energy Corporation securities between February 27, 2025, and July 8, 2026, face a September 28, 2026, deadline to seek lead plaintiff status. Rosen Law Firm is currently organizing the class action following allegations that the company misled shareholders regarding its reliance on Chinese scandium.

Investors Face September Deadline in Bloom Energy Securities Lawsuit
Photo: Bio & News

The lawsuit centers on claims that Bloom Energy obscured its supply chain practices by failing to disclose that it sourced scandium through intermediaries linked to China. According to the complaint, these omissions rendered the company's public statements regarding its business operations and financial prospects materially misleading. Investors allege that the eventual disclosure of these details caused significant financial harm.

Those who bought shares during the specified period may be eligible for compensation through a contingency fee arrangement, meaning no out-of-pocket costs are required to join. While a lawsuit has already been initiated, no class has yet been certified. Investors retain the option to hire their own counsel, remain as absent class members, or move the court to serve as a lead plaintiff to help direct the litigation. Interested parties can contact Phillip Kim at Rosen Law Firm to review their participation options before the court deadline.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!